阿罗洛尔对慢性心力衰竭患者血清N端脑钠肽前体的影响

Effects of arotinolol on serum NT-proBNP in patients with chronic heart failure

目的观察阿罗洛尔对慢性心力衰竭患者血清N端脑钠肽前体(NT-proBNP)水平的影响。方法将80例慢性心力衰竭患者随机分为阿罗洛尔组和常规治疗组。常规治疗组(n=40)应用血管紧张素转换酶抑制剂、利尿剂和洋地黄制剂,阿罗洛尔组(n=40)在此基础上加用阿罗洛尔(目标剂量10 mg,2次/d),疗程均为12周。在治疗前和12周末采静脉血检测两组患者的NT-proBNP水平。结果治疗后两组NT-proBNP水平均较治疗前明显下降(P<0.05)。治疗后阿罗洛尔组NT-proBNP水平显著低于常规治疗组(P<0.05)。结论阿罗洛尔能降低心力衰竭患者的NT-proBNP水平,并改善慢性心力衰竭患者的心功能。

Objective To investigate effects of arotinolol on serum N terminal brain natriuretic peptide （NT- proBNP） in patients with chronic heart failure. Methods 80 patients were randomly divided into arotinolol group and conventional therapy group. Patients of conventional therapy group （ n = 40） were treated with angiotensin converting enzyme inhibitors, diuretics and digitalis, while the arotinolol group（ n = 40） were assigned to treatment with arotinolol （ target dose 10mg twice daily） at the basis of conventional therapy. All the patients were treated for 12 weeks. Venous samples for NT-proBNP level determination were drawn before treatment and at the end of week 12. Results Levels of serum NT-pruBNP declined obviously in both groups after treatment （P 〈 0. 05 ）. Moreover, NT-proBNP was lower in the patients of arotinolol group than those in the conventional therapy group （P 〈 0.05 ）. Conclusion Arotinolol can reduce serum NT-proBNP levels and exerts beneficial effects on the improvement of cardiac functions in patients with chronic heart failure.